Clinical trials: Durvalumab
Advanced Non Small Cell Lung Cancer
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
- Trial name
- NCT02143466
- Testing
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- Where
- 42 sites in United States, Canada and 6 more
- Volunteers
- 344 people
- Sponsor
- AstraZeneca
Papillary Renal Cell Carcinoma
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell…
- Trial name
- SAMETA (NCT05043090)
- Testing
- savolitinib, durvalumab, sunitinib
- Where
- 139 sites in United States, Argentina and 23 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in…
- Trial name
- NeoCOAST-2 (NCT05061550)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 97 sites in United States, Belgium and 10 more
- Volunteers
- 630 people
- Sponsor
- AstraZeneca
Breast Cancer
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with…
- Trial name
- NCT06112379
- Testing
- Dato-DXd, Durvalumab, Pembrolizumab
- Where
- 283 sites in United States, Australia and 24 more
- Volunteers
- 1,902 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C.
- Trial name
- NCT07554339
- Testing
- Calderasib, Durvalumab
- Where
- 98 sites in United States, Argentina and 16 more
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
- Trial name
- EMERALD-3 (NCT05301842)
- Testing
- Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE)
- Where
- 171 sites in United States, Belgium and 20 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Trial of INI-4001 in Patients With Advanced Solid Tumours
Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.
- Trial name
- NCT06302426
- Testing
- INI-4001, Nivolumab, Pembrolizumab
- Where
- 3 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Inimmune Corporation
Gastric, Esophagogastric Junction
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
This study aims to assess the efficacy and safety of neoadjuvant adjuvant treatment with durvalumab in combination with FLOT compared to placebo in combination with FLOT in Chinese patients with Resectable Gastric and…
- Trial name
- NCT07877818
- Testing
- FLOT Chemotherapy, Durvalumab
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Muscle Invasive Bladder Cancer
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
- Trial name
- NIAGARA (NCT03732677)
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 1,063 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Muscle-Invasive Bladder Cancer (MIBC)
A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive
This is a Phase 4, Single Arm Study To Assess The Safety and tolerability of Perioperative Durvalumab in Combination with Neoadjuvant Gemcitabine Plus Cisplatin Treatment Followed by radical cystectomy and Durvalumab alone as…
- Trial name
- SERENE (NCT07876817)
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with…
- Trial name
- NCT05629585
- Testing
- Dato-DXd, Durvalumab, Capecitabine
- Where
- 276 sites in United States, Belgium and 15 more
- Volunteers
- 1,174 people
- Sponsor
- AstraZeneca
Esophageal Squamous Cell Carcinoma
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced…
- Trial name
- KUNLUN (NCT04550260)
- Testing
- Durvalumab, cisplatin + fluorouracil, cisplatin + capecitabine
- Where
- 133 sites in United States, Belgium and 14 more
- Volunteers
- 640 people
- Sponsor
- AstraZeneca
Biliary Tract Cancer
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing…
- Trial name
- DESTINY-BTC01 (NCT06467357)
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 272 sites in United States, Australia and 25 more
- Volunteers
- 620 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
- Trial name
- TREMENDOUS-2 (NCT07081633)
- Testing
- Durvalumab, Tremelimumab, Lenvatinib
- Where
- 23 sites in China, Hong Kong
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
NSCLC
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in…
- Trial name
- AVANZAR (NCT05687266)
- Testing
- Datopotamab deruxtecan, Durvalumab, Carboplatin
- Where
- 254 sites in United States, Austria and 21 more
- Volunteers
- 1,350 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
- Trial name
- EMERALD-2 (NCT03847428)
- Testing
- Durvalumab, Bevacizumab
- Where
- 217 sites in United States, Australia and 22 more
- Volunteers
- 908 people
- Sponsor
- AstraZeneca
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to…
- Trial name
- SUNRAY-02 (NCT06890598)
- Testing
- Olomorasib, Pembrolizumab, Durvalumab
- Where
- 366 sites in United States, Australia and 27 more
- Volunteers
- 700 people
- Sponsor
- Eli Lilly and Company